Spatially segregated multiomics decodes metformin-mediated function-specific metabolic characteristics in diabetic kidney disease

Abstract

Understanding the specific metabolic changes in multiple regions of the kidney is crucial to revealing the underlying mechanism and developing effective targets for diabetic nephropathy (DN). In this study, integrated spatially resolved metabolomics and proteomics combined with mass spectrometry imaging (MSI) revealed a multi-scale region profile of the diabetic kidney. Based on anatomic location, spatial metabolomics revealed eight region-specific metabolite biomarkers uniquely localized to kidney segments, which were closely correlated to the clinical parameters of patients with DN. Specifically, treatment with metformin (MET) enriched inosinic acid, adenosine 3',5'-diphosphate, nicotinamide adenine dinucleotide (NADH), and hydrated NADH (NADHX) levels in the cortex (Cor) and the outer stripe of kidney medulla (OM) anatomical subregions, while in the inner stripe of kidney medulla (IM) segmentation, the p-cresol sulfate level was downregulated. Comparing differently expressed proteins in each region showed that nephrosis 2 (Nphs2) was the highest loading feature. A further region-specific analysis of pathway enrichment characteristics indicated that the purine and ether lipid metabolism pathways were enriched in the Cor and OM regions, whereas the pantothenate and coenzyme A (CoA) biosynthesis pathways were mainly enriched in the IM region in response to MET treatment. Taken together, the spatially segregated metabolomics and proteomics studies reveal MET-mediated proteins and function-specific therapeutic pathways related to the anatomical multiregion of diabetic mouse kidneys.

Keywords

spatial metabolomics / spatial proteomics / anatomic multiregion / metabolism / target

References

[1] Mohan V , Anjana RM . Why does visceral adiposity not explain higher type 2 diabetes prevalence in Asian Indians? Lancet Diabetes Endocrinol 2024; 12: 682- 3.

[2] Wysham C , Bajaj HS , Del Prato S et al. Insulin efsitora versus degludec in type 2 diabetes without previous insulin treatment. N Engl J Med 2024; 391: 2201- 11.

[3] Ammon JP , Jackson CD . Semaglutide, obesity-related heart failure, and type 2 diabetes. N Engl J Med 2024; 391: 381.

[4] Pathak V , Bertelli PM , Pedrini E et al. Modulation of diabetesrelated retinal pathophysiology by PTX3. Proc Natl Acad Sci USA 2024; 121: e2320034121.

[5] Lake BB , Menon R , Winfree S et al. An atlas of healthy and injured cell states and niches in the human kidney. Nature 2023; 619: 585- 94.

[6] Schwartz L , Simoni A , Yan P et al. Insulin receptor orchestrates kidney antibacterial defenses. Proc Natl Acad Sci USA 2024; 121: e2400666121.

[7] Zhuang X , Sun Z , Du H et al. Metformin inhibits high glucoseinduced apoptosis of renal podocyte through regulating miR- 34a/SIRT1 axis. Immun Inflamm Dis. 2024; 12: e1053.

[8] Ma M , Pan Y , Zhang Y et al. Metformin combined with rapamycin ameliorates podocyte injury in idiopathic membranous nephropathy through the AMPK/mTOR signaling pathway. J Cell Commun Signal. 2023; 17: 1405- 15.

[9] Sánchez-Garrido MA , Serrano-López V , Ruiz-Pino F et al. Superior metabolic improvement of polycystic ovary syndrome traits after GLP1-based multi-agonist therapy. Nat Commun 2024; 15: 8498.

[10] Wang Z , Li K , Lu C et al. Metformin promotes anti-tumor immunity in STK11 mutant NSCLC through AXIN1-dependent upregulation of multiple nucleotide metabolites. Oncol Res 2024; 32: 1637- 48.

[11] Qiu S , Wang Z , Guo S et al. Single cell sequencing and spatial multiomics of diabetic kidney segmentation insights zonation-specific therapeutic metabolic pathways. Cell Insight 2025; 4: 100252.

[12] Qiu S , Guo S , Wang Z et al. Integrated metabolomics and proteomics revealed astragaloside IV inhibiting Pdxk-mediated vitamin B6 metabolism based on liquid chromatographytandem mass spectrometry combined with pattern recognition and correlation analysis. J Funct Foods 2025; 124: 106654.

[13] Wada Y , Kidokoro K , Kondo M et al. Evaluation of glomerular hemodynamic changes by sodium-glucose-transporter 2 inhibition in type 2 diabetic rats using in vivo imaging. Kidney Int 2024; 106: 408- 18.

[14] Qiu S , Guo S , Xie D et al. Comprehensive multiomics revealed astragaloside IV regulating carbohydrate metabolism dysfunction through clinical, animal and cellular platforms. Food Bioscience 2025; 68: 106757.

[15] Qiu S , Cai Y , Yao H et al. Small molecule metabolites:discovery of biomarkers and therapeutic targets. Signal Transduct Target Ther 2023; 8: 132.

[16] Hicks KG , Cluntun AA , Schubert HL et al. Protein-metabolite interactomics of carbohydrate metabolism reveal regulation of lactate dehydrogenase. Science 2023; 379: 996- 1003.

[17] Yang Q , Cai Y , Guo S et al. Localization analysis of metabolites from complex biological samples-recent analytical technique of mass spectrometry imaging. Front Mol Biosci. 2023; 10: 1169449.

[18] Heuckeroth S , Behrens A , Wolf C et al. On-tissue dataset-dependent MALDI-TIMS-MS2 bioimaging. Nat Commun 2023; 14: 7495.

[19] Lin C , Tian Q , Guo S et al. Metabolomics for clinical biomarker discovery and therapeutic target identification. Molecules 2024; 29: 2198.

[20] Kondo A , McGrady M , Nallapothula D et al. Spatial proteomics of human diabetic kidney disease, from health to class Ⅲ. Diabetologia 2024; 67: 1962- 79.

[21] Chai J , Wang Y , Guo S et al. Proteomics exploration of metformin hydrochloride for diabetic kidney disease treatment via the butanoate metabolism pathway. J Pharm Biomed Anal 2025; 254: 116584.

[22] Sun N , Krauss T , Seeliger C et al. Inter-organ cross-talk in human cancer cachexia revealed by spatial metabolomics. Metabolism. 2024; 161: 156034.

[23] Zhou X , Zhou J , Ban Q et al. Effects of metformin on the glucose regulation, lipid levels and gut microbiota in high-fat diet with streptozotocin induced type 2 diabetes mellitus rats. Endocrine 2024; 86: 163- 72.

[24] Petrie JR . Metformin beyond type 2 diabetes:emerging and potential new indications. Diabetes Obes Metab 2024; 26: 31- 41.

[25] Wang HH , Lin SH , Hung SY et al. Renal protective effect of metformin in type 2 diabetes patients. J Clin Endocrinol Metab 2025; 110: 1224- 34.

RIGHTS & PERMISSIONS

The Author(s). Published by Oxford University Press on behalf of Higher Education Press.